|
EP2982764A1
|
|
Identification of vaginal bacteria
|
|
US2015017149A1
|
|
Method of treating GERD with alpha and beta galactosidases
|
|
CN105324109A
|
|
NSAID administration and related compositions, methods and systems
|
|
US2016047819A1
|
|
Method for diagnosing vaginal infections
|
|
CA2897758A1
|
|
Rifaximin for use in the treating of vaginal infections
|
|
AU2013212008A1
|
|
Rifaximin derivative and uses thereof
|
|
UA111972C2
|
|
Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections
|
|
HUE025669T2
|
|
Pharmaceutical compositions containing beta- and alpha-galactosidase and their use in the treatment of gastroesophageal reflux disease
|
|
ITBO20120226A1
|
|
COMPOSITIONS INCLUDING ALPINE-KETOGLUTARATE ORNITINE, PROCESSES FOR THEIR ACHIEVEMENT AND THEIR USE.
|
|
EP2651392A1
|
|
Solid compositions containing flurbiprofen, the processes for their preparation and their use.
|
|
RU2557996C2
|
|
Sulodexide applicable in treating pathologies involving metalloproteinases
|
|
ITBO20110012A1
|
|
PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
|
|
ITMI20100370A1
|
|
RIFAXIMINA COMPREHENSIVE FORMULATIONS USEFUL TO OBTAIN A PROLONGED EFFECT IN TIME
|
|
US2008262232A1
|
|
Processes for the production of polymorphic forms of rifaximin
|
|
US2008262012A1
|
|
Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
|
|
US2008262220A1
|
|
Polymorphic forms α, β and γ of rifaximin
|
|
TW200904415A
|
|
Improved bioavailability of antibiotics
|
|
MY150692A
|
|
Gastroresistant pharmaceutical formulations containing rifaximin
|
|
MY144578A
|
|
New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
|
|
JO2946B1
|
|
Improved Bioavailability Of Antibiotics
|
